Actively Recruiting
Comparing Sacituzumab Tirumotecan Plus Pembrolizumab Versus Physicians Choice Treatment for Triple-Negative Breast Cancer After Neoadjuvant Therapy Without Complete Response
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-13
1530
Participants Needed
314
Research Sites
365 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of an adjuvant treatment combining sacituzumab tirumotecan with pembrolizumab compared to treatment chosen by physicians in people with triple-negative breast cancer TNBC who received neoadjuvant therapy but did not achieve a complete response at surgery. This Phase 3, randomized, open-label study aims to determine if the combination improves invasive disease-free survival compared to pembrolizumab alone or pembrolizumab combined with capecitabine. Participants are randomly assigned to one of two groups. One group receives pembrolizumab every 6 weeks along with sacituzumab tirumotecan every 2 weeks for a total of 24 weeks, with premedication including antihistamines, H2 antagonists, acetaminophen, and dexamethasone before sacituzumab tirumotecan infusions. The other group receives pembrolizumab every 6 weeks alone or combined with capecitabine taken orally twice daily on specific days over 24 weeks. The study treatments are given intravenously or by mouth according to schedule. During the study, participants undergo regular assessments to monitor disease status, quality of life, and adverse events. Researchers measure invasive disease-free survival for up to approximately 77 months, along with overall survival and distant recurrence-free survival for up to about 101 months. Quality of life is evaluated using standardized questionnaires at baseline and periodically for up to 60 months. Safety is closely monitored, including recording adverse events and treatment discontinuations. The total study duration may last over a decade, with long-term follow-up to assess outcomes and treatment effects.
CONDITIONS
Brief Title
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here